Conference Coverage

VIDEO: Best practices in treating low testosterone in men


 

EXPERT ANALYSIS FROM AACE 2014

LAS VEGAS – Analysis of data from a company that provides therapy for low testosterone showed that the treatment was not associated with a higher risk of myocardial infarction and stroke in men, and it may have played a protective role.

The findings clash with what two recent studies – one published in JAMA and the other in PLoS One – found, which showed that testosterone therapy increased the risk of MI and stroke in men, prompting the Food and Drug Administration to reassess the safety of the approved treatments.

Dr. Aaron Vinik, Murray Waitzer Endowed Chair for Diabetes Research at Eastern Virginia Medical School, Norfolk, puts the studies in perspective in this interview, and shares how patients should be treated based on current data and available knowledge.

nmiller@frontlinemedcom.com On Twitter @naseemsmiller

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Polyp, adenoma detection rises with Endocuff device
MDedge Endocrinology
Empagliflozin improves glycemia, blood pressure in type 2 diabetes study
MDedge Endocrinology
20-study analysis finds no MACE increase with saxagliptin
MDedge Endocrinology
Canagliflozin effects include weight loss in phase III placebo-controlled trial
MDedge Endocrinology
Sex, ancestry play roles in diabetes rates in Hispanics
MDedge Endocrinology
VIDEO: U.S. Hispanics show varying diabetes rates by country of origin
MDedge Endocrinology
Evolocumab lowers LDL-C with no effect on glucose metabolism
MDedge Endocrinology
Testosterone is insulin sensitizing in diabetic men with hypogonadism
MDedge Endocrinology
Testosterone therapy may not be associated with CV risk
MDedge Endocrinology
Liraglutide gains clout as weight loss agent for overweight, nondiabetic patients
MDedge Endocrinology

Related Articles